CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock?

Core Insights - CareDx (CDNA) shares increased by 11.2% to $24.91, following a significant trading volume, contrasting with a 5.2% decline over the past month [1] - The upcoming fourth-quarter 2024 financial results are anticipated to show approximately 30% year-over-year revenue growth, with testing services volume increasing by 14% [2] - The consensus EPS estimate for the quarter is $0.07, reflecting a year-over-year increase of 141.2%, with expected revenues of $85.5 million, up 30.4% from the previous year [3] Earnings and Revenue Expectations - Adjusted EBITDA is projected to be between $25 million and $26 million for the fourth quarter [2] - The consensus EPS estimate has been revised 13.2% higher in the last 30 days, indicating a positive trend that typically leads to price appreciation [4] Industry Context - CareDx is part of the Zacks Medical Services industry, which includes other companies like LifeMD, Inc. (LFMD), that saw a 5.5% increase in its last trading session [4] - LifeMD's EPS estimate remains unchanged at -$0.06, representing a 50% year-over-year change [5]